This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

14 Aug 2013

Amgen and Servier Complete Product Collaborat?ion Transactio?n

Amgen and Servier have announced the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced on 8 July 2013, completing the transaction.

Under the terms of the agreement, Amgen has obtained commercial rights in the US to Servier's novel oral drug, approved in the EU as Procoralan (ivabradine), for chronic heart failure and stable angina in patients with elevated heart rates.

Amgen has also received an exclusive option to develop and commercialise Servier's investigational molecule, S38844, for cardiovascular diseases in the US Currently, S38844 is in Phase II studies for the treatment of heart failure. Through the collaboration, Servier has obtained an exclusive option to commercialise omecamtiv mecarbil in Europe. Omecamtiv mecarbil is an activator of cardiac myosin, which is currently being tested for potential applications in the treatment of heart failure in patients with systolic dysfunction.

Related News